Eloise Kuijer, our PhD student with the University of Bath, will be presenting the results of her research into the effects of activating kappa opioid receptors at KappaCon 2023
This paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens and entactogens for new drug applications to the FDA and scheduling recommendations.
Our latest paper describing screening strategies for drug discovery and development to deliver more effective and safer psychedelics and entactogens for clinical use is now available online
Congratulations to David Heal on being elected an Honorary Fellow of the British Pharmacological Society for sustained excellence in research, including drug discovery and development
David Heal will be attending the 61st Annual Meeting of the ACNP (American College of Neuropsychopharmacology), 4th to 7th December 2022, JW Marriott Desert Ridge Resort and Spa, Phoenix, Arizona. If you would like to see David at the ACNP to discuss our consultancy services in the areas of drug abuse evaluation and CNS and metabolic disorders please contact email@example.com.